文献速递肿瘤 PET/CT

新型PET示踪剂鉴别转移性睾丸生殖细胞肿瘤化疗后残留肿块性质的系统综述

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-02

αvβ3靶向显像在临床前研究中显示区分成熟畸胎瘤与坏死的前景,ghrelin受体示踪剂因在TGCTs中高表达而有前景但尚处临床前阶段,claudin-6在多数TGCT组织学类型中高表达且早期临床试验支持其作为可行分子靶点。新型PET示踪剂有望优化TGCT管理,但常规应用前需进一步临床验证。

要点

  • αvβ3整合素靶向显像在临床前研究中显示区分成熟畸胎瘤与坏死的前景。
  • Ghrelin受体示踪剂在TGCTs中高表达,但尚处临床前开发阶段。
  • Claudin-6在多数TGCT组织学类型中高表达,早期临床试验支持其作为可行分子靶点。

核心结论

  • 新型PET示踪剂是优化睾丸生殖细胞肿瘤管理的 promising 途径,其中αvβ3整合素和ghrelin基示踪剂在指导化疗后决策方面尤其值得关注,但常规实施前需进一步临床验证。

主要发现

  • 评估的新兴PET示踪剂包括[18F]-FLT、FAPI、αvβ3整合素靶向药物、[18F]-fluciclovine、PSMA靶向示踪剂以及基于ghrelin和claudin-6的示踪剂。
  • αvβ3靶向显像在临床前研究中显示区分成熟畸胎瘤与坏死的前景。
  • Ghrelin受体示踪剂因在TGCTs中高表达而有前景,但仍处于临床前开发阶段。
  • Claudin-6在多数TGCT组织学类型中高表达,早期临床试验支持其作为可行分子靶点。

临床怎么用

  • 新型PET示踪剂有望指导TGCT化疗后残留肿块的管理决策,可能显著减少过度治疗并增强个体化护理。

局限性

  • 新型PET示踪剂在常规实施前需要进一步的临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Testicular germ cell tumours (TGCTs) are the most common malignancy in young adult males. After chemotherapy, the evaluation of residual masses is critical. However, the current standard imaging modality, [18F]-FDG PET, has limited specificity-particularly in distinguishing viable tumour from necrosis or mature teratoma. This limitation often leads to unnecessary surgery or misinterpretation of treatment response. OBJECTIVES: This systematic review aims to explore and evaluate novel PET tracers that could improve diagnostic accuracy in TGCTs, especially in post-chemotherapy settings. METHODS: A comprehensive literature search was conducted on PubMed and Scopus through December 2025, using terms including "testicular," "germ cell tumour," "PET scan," and "novel." Studies focusing solely on [18F]-FDG were excluded. Preclinical studies, case reports, and clinical trials investigating alternative PET tracers or relevant molecular targets (e.g., ghrelin, claudin-6) were included. The quality of selected articles was assessed by using CASP for the qualitative research. RESULTS: A total of 17 studies met the inclusion criteria. Emerging PET tracers evaluated include [18F]-FLT, FAPI, αvβ3-integrin-targeted agents, [18F]-fluciclovine, PSMA-targeted tracers, and those based on ghrelin and claudin-6. Among these, αvβ3-targeted imaging has shown promising preclinical results in differentiating mature teratoma from necrosis. Ghrelin receptor tracers appear promising due to their high expression in TGCTs, although they remain in preclinical development. Claudin-6, a tight-junction protein, is highly expressed in most TGCT histologies and may be a viable molecular target, as supported by early-phase clinical trials. CONCLUSIONS: Novel PET tracers represent a promising avenue to refine TGCT management. αvβ3-integrin and ghrelin-based tracers are particularly noteworthy for their potential to guide decision-making after chemotherapy. However, further clinical validation is required before routine implementation. These innovations could significantly reduce overtreatment and enhance personalized care in TGCT patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bertocchi A, De Vincenzo F, Perrino M, et al. Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review. Eur J Nucl Med Mol Imaging. 2026. PMID: 42390562. doi:10.1007/s00259-026-08044-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。